AIM ImmunoTech Inc. (AIM)
| Market Cap | 5.40M -24.1% |
| Revenue (ttm) | 95,000 -21.5% |
| Net Income | -14.27M |
| EPS | -2.14 |
| Shares Out | 30.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 482,808 |
| Open | 0.1800 |
| Previous Close | 0.1800 |
| Day's Range | 0.1764 - 0.1815 |
| 52-Week Range | 0.1659 - 2.7910 |
| Beta | 1.27 |
| Analysts | Buy |
| Price Target | 4.25 (+2,295.72%) |
| Est. Earnings | Nov 4, 2026 |
About AIM
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also ... [Read more]
Financial Performance
In 2025, AIM ImmunoTech's revenue was $88,000, a decrease of -48.24% compared to the previous year's $170,000. Losses were -$13.96 million, -19.41% less than in 2024.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for AIM stock is "Buy." The 12-month stock price target is $4.25, which is an increase of 2,295.72% from the latest price.
News
AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays
CEO interview explores Ampligen's potential to extend survival and improve quality of life as AIM advances toward pivotal development
AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential
OCALA, Fla., Oct. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted recent media coverage of the antiviral potential of Ampligen® (rintat...
AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
Recent biotech media features focus on Ampligen's potential to address immune resistance in metastatic pancreatic cancer and the clinical progress of the Phase 2 DURIPANC program Recent biotech media...
AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video
Company highlights supportive survival observations, potential for biomarker-driven patient selection and upcoming Phase 2 DURIPANC milestones
AIM ImmunoTech Proxy statement: Proxy filing
AIM ImmunoTech filed a proxy statement on September 30, 2026, providing details for shareholder voting and corporate governance matters.
AIM ImmunoTech CEO issues letter to stockholders
AIM ImmunoTech (AIM) issued a letter to stockholders from Chief Executive Officer Thomas Equels addressing the recent U.S. Food and Drug Administration approval of daraxonrasib and outlining the Compa...
AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib
Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall surviv...
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
Company continues to advance Phase 2 DURIPANC study and broader clinical strategy evaluating Ampligen's potential to reshape the tumor microenvironment and enhance checkpoint inhibition
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
Patent protections establish long-duration intellectual property coverage for Ampligen across major European markets and the United Kingdom
AIM ImmunoTech granted patent for Ampligen
AIM ImmunoTech (AIM) announced that the United States Patent and Trademark Office has granted a patent covering the use of the company’s drug Ampligen in combination with the PD-1 checkpoint…
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
OCALA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Patent and Trademark Office has granted a patent...
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference
Video webcast now available here
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense' Article
Article by CEO Thomas K. Equels calls for proactive evaluation of broad-spectrum antiviral countermeasures before novel viral threats emerge
AIM ImmunoTech Quarterly report: Q2 2026
AIM ImmunoTech has published its Q2 2026 quarterly earnings report on August 7, 2026.
AIM ImmunoTech Earnings release: Q2 2026
AIM ImmunoTech released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
AIM ImmunoTech Ahead of Schedule on ‘Last Dose' DURIPANC Critical Clinical Inflection Point
Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December...
AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent cli...
AIM ImmunoTech Proxy statement: Proxy filing
AIM ImmunoTech filed a proxy statement on June 25, 2026, providing details for shareholder voting and corporate governance matters.
AIM ImmunoTech Accelerates Toward Potential Pivotal Pancreatic Cancer Program as Ampligen Continues to Advance Through Key Clinical Milestones
OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer develo...
AIM Sports Group's National SoCal Cup ‘The Showcase' Event Serves Up a Weekend of New Experiences
LOS ANGELES--(BUSINESS WIRE)-- #aimsportsgroup--AIM Sports Group hosted the SoCal Cup ‘Showcase' tournament, one of the nation's leading tournament series for youth club volleyball, at the Los Angeles...
AIM ImmunoTech to Present in the Webull Corporate Connect Webinar Series
OCALA, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that it will present in the Webull Corporate Connect Webinar Series bei...
AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer Study results expected to support design and initiation of ...
AIM ImmunoTech Registration statement: Registration filing
AIM ImmunoTech filed a registration statement on June 18, 2026, providing details about a securities offering with the SEC.
AIM Talks China 2026 Convenes in Guangzhou, Advancing Strategic Partnerships and Cross Border Investment Across the Greater Bay Area
GUANGZHOU, China , June 17, 2026 (GLOBE NEWSWIRE) -- As global capital, industrial transformation, and cross border trade realign around new growth corridors, AIM Talks China 2026 convened investors, ...
AIM ImmunoTech Regains NYSE American Compliance, Company Resolves Stockholder Equity Deficiency
OCALA, Fla., June 15, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM,” or the “Company”), an immuno-pharma company focused on the development of therapeutics to treat multiple...